Louisiana Challenges FDA on Mifepristone Access in High-Stakes Abortion Drug Case — Family Research Council

Event summary

Louisiana v. FDA oral arguments held February 24, 2026, challenging FDA's permissive stance on mifepristone.
Family Research Council (FRC) supports Louisiana, citing 600-800 estimated illegal chemical abortions monthly in Louisiana.
FRC's amicus brief highlights 118,338 abortion drug packs mailed by a telemedicine service between July 2023 and September 2024.
FRC argues FDA ignores coercion risks in remote abortion drug prescriptions.

The big picture

This case represents a critical clash between state sovereignty and federal regulatory authority in the post-Roe era. The outcome could reshape abortion access, particularly through medication, and set precedents for how telemedicine services are regulated. The involvement of pro-life states and advocacy groups underscores the high stakes in this ongoing legal battle.

What we're watching

Regulatory Outcomes: Whether the court will grant relief to Louisiana, potentially restricting FDA's mifepristone regulations.
Public Health Impact: How the case may affect abortion access and safety in states with restrictive laws.
Telemedicine Regulation: The pace at which regulators address coercion risks in remote abortion drug prescriptions.